The company, in an exchange filing said it has received the permission from the CDSCO for the drug’s 100mg/5ml lyophilized powder for concentrate for solution for infusion (brand name: Enhertu) for an additional indication.
The company, in an exchange filing said it has received the permission from the CDSCO for the drug’s 100mg/5ml lyophilized powder for concentrate for solution for infusion (brand name: Enhertu) for an additional indication.